• Explore /
  • Poster
  • / Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH.

Real-world clinical outcomes study of sequential novel antihormonal therapy (NAH) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH.

Abstract Video & Slides Poster

Authors

A. Sartor

Oliver A. Sartor

Tulane University School of Medicine, New Orleans, LA

Oliver A. Sartor , Daniel J. George , Bertrand Tombal , Celestia S. Higano , Cora N. Sternberg , Kurt Miller , Xiaolong Jiao , Helen Guo , Per Sandstrom , Frank Verholen , Fred Saad , Neal D. Shore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Clinical Trial Registration Number

NCT03896984

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 48)

DOI

10.1200/JCO.2021.39.6_suppl.48

Abstract #

48

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Daniel J. George

First Author: Neal D. Shore

First Author: Daniel J. George

First Author: Elena Castro